World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
10502
World Ranking
3551
National Ranking
1642

Bradley E. Chipps publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Bradley E. Chipps sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 448 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Bradley E. Chipps D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Bradley E. Chipps sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 58 D-Index — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Bradley E. Chipps is affiliated with the American College of Allergy, Asthma and Immunology in the United States. Their research primarily focuses on medicine, with extensive work in subfields such as physiology, pulmonary and respiratory medicine, immunology and allergy, surgery, and pediatrics, perinatology, and child health.

The main topics covered in their research include:

  • Asthma and respiratory diseases
  • Respiratory and cough-related research
  • Inhalation and respiratory drug delivery
  • Chronic obstructive pulmonary disease (COPD) research
  • Allergic rhinitis and sensitization
  • Eosinophilic esophagitis
  • Pharmaceutical studies and practices

Bradley E. Chipps has published frequently in several key venues:

  • Annals of Allergy Asthma & Immunology (48 publications)
  • Journal of Allergy and Clinical Immunology (31 publications)
  • The Journal of Allergy and Clinical Immunology In Practice (21 publications)
  • CHEST Journal (6 publications)
  • Journal of Asthma and Allergy (6 publications)

Their recent papers include:

  • "T2-'Low' Asthma: Overview and Management Strategies", 2020, The Journal of Allergy and Clinical Immunology In Practice
  • "Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma", 2022, New England Journal of Medicine
  • "Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment", 2023, Annals of Allergy Asthma & Immunology
  • "Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis", 2020, Annals of Allergy Asthma & Immunology
  • "Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure", 2020, The Journal of Allergy and Clinical Immunology In Practice

Frequent co-authors collaborating with Bradley E. Chipps include:

  • Reynold A. Panettieri
  • Ileen Gilbert
  • Alberto Papi
  • Robert S. Zeiger
  • James M. Eudicone

Best Publications

  • Design and baseline characteristics of The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma

    Chantal M. Dolan;Kyle E. Fraher;Eugene R. Bleecker;Larry Borish

  • Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study

    Thomas B. Casale;Allan T. Luskin;William Busse;Robert S. Zeiger

  • Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma

    Michael Schatz;Jin-Wen Y. Hsu;Robert S. Zeiger;Wansu Chen

  • Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study

    Bradley E. Chipps;Robert S. Zeiger;Larry Borish;Sally E. Wenzel

  • Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma

    S D Sullivan;L Rasouliyan;P A Russo;T Kamath

  • Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study.

    June H. Lee;Tmirah Haselkorn;Larry Borish;Lawrence Rasouliyan

  • A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.

    Dennis Ledford;William Busse;Benjamin Trzaskoma;Theodore A. Omachi

  • Allergy testing in childhood: Using allergen-specific IgE tests

    Scott H. Sicherer;Robert A. Wood;Stuart Abramson;Bradley E. Chipps

  • Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study.

    Tmirah Haselkorn;James E. Fish;Robert S. Zeiger;Stanley J. Szefler

  • Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma

    Larry Borish;Bradley Chipps;Yamo Deniz;Sheila Gujrathi

  • Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.

    Jonathan Corren;Mario Castro;Thomas O'Riordan;Nicola A. Hanania

  • Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.

    Thomas B. Casale;Bradley E. Chipps;Karin Rosén;Benjamin Trzaskoma

  • The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

    Kenneth R. Chapman;Frank C. Albers;Bradley Chipps;Xavier Muñoz

  • Test for Respiratory and Asthma Control in Kids (TRACK) : A caregiver-completed questionnaire for preschool-aged children

    Kevin R. Murphy;Robert S. Zeiger;Mark Kosinski;Bradley Chipps

  • Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience.

    Bradley E. Chipps;Bob Lanier;Henry Milgrom;Antoine Deschildre

  • Section on allergy and immunology

    Stuart L. Abramson;James R. Banks;Arnold;Theresa A. Bingemann

  • Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma

    Trung N. Tran;Robert S. Zeiger;Stephen P. Peters;Gene Colice

  • Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma

    Tmirah Haselkorn;Robert S. Zeiger;Bradley E. Chipps;David R. Mink

  • Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma.

    Allan T. Luskin;Bradley E. Chipps;Lawrence Rasouliyan;Dave P. Miller

  • The Childhood Asthma Control Test∗: Retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma

    Andrew H. Liu;Robert S. Zeiger;Christine A. Sorkness;Nancy K. Ostrom

  • T2-"Low" Asthma: Overview and Management Strategies.

    Anne M. Fitzpatrick;Bradley E. Chipps;Fernando Holguin;Prescott G. Woodruff

  • Economic burden of impairment in children with severe or difficult-to-treat asthma

    Stanley J. Szefler;Robert S. Zeiger;Tmirah Haselkorn;David R. Mink

Frequent Co-Authors

Robert S. Zeiger
Robert S. Zeiger Kaiser Permanente
Stanley J. Szefler
Stanley J. Szefler University of Colorado Denver
Reynold A. Panettieri
Reynold A. Panettieri Rutgers, The State University of New Jersey
Thomas B. Casale
Thomas B. Casale University of South Florida
Donald P. Tashkin
Donald P. Tashkin University of California, Los Angeles
Wendy C. Moore
Wendy C. Moore Wake Forest University
William W. Busse
William W. Busse University of Wisconsin–Madison
Eugene R. Bleecker
Eugene R. Bleecker University of Arizona
Nicola A. Hanania
Nicola A. Hanania Baylor College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, pursuing related healthcare degrees online can open diverse career opportunities. Those aiming to specialize in mental health may consider exploring the cheapest psych np programs online, which offer affordable pathways to become psychiatric nurse practitioners.

Advanced nursing roles such as Doctor of Nursing Practice (DNP) can be highly rewarding, with compensation varying by location. To understand potential earnings, it's helpful to review data on how much do dnps make, helping students plan their educational investment accordingly.

Nurses looking to expand their expertise might explore transitioning from family-focused practice to more specialized care. Resources on fnp to acnp transitions provide valuable guidance for those interested in acute care roles.

For those ready to accelerate their education, programs like the accelerated fnp program offer streamlined online pathways to become family nurse practitioners, combining flexibility with rigorous training.

Best Scientists Citing Bradley E. Chipps

Trending Scientists

Recently Published Articles